BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

975 related articles for article (PubMed ID: 16024619)

  • 21. Loss of heterozygosity and somatic mutations of the VHL tumor suppressor gene in sporadic cerebellar hemangioblastomas.
    Lee JY; Dong SM; Park WS; Yoo NJ; Kim CS; Jang JJ; Chi JG; Zbar B; Lubensky IA; Linehan WM; Vortmeyer AO; Zhuang Z
    Cancer Res; 1998 Feb; 58(3):504-8. PubMed ID: 9458097
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Role of hypoxia-inducible factor (HIF)-1alpha versus HIF-2alpha in the regulation of HIF target genes in response to hypoxia, insulin-like growth factor-I, or loss of von Hippel-Lindau function: implications for targeting the HIF pathway.
    Carroll VA; Ashcroft M
    Cancer Res; 2006 Jun; 66(12):6264-70. PubMed ID: 16778202
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Hypoxia mediated expression of stem cell markers in VHL-associated hemangioblastomas.
    Ponnaluri VK; Vavilala DT; Prakash S; Mukherji M
    Biochem Biophys Res Commun; 2013 Aug; 438(1):71-7. PubMed ID: 23872148
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Loss of HNF1alpha function in human renal cell carcinoma: frequent mutations in the VHL gene but not the HNF1alpha gene.
    Lemm I; Lingott A; Pogge v Strandmann E; Zoidl C; Bulman MP; Hattersley AT; Schulz WA; Ebert T; Ryffel GU
    Mol Carcinog; 1999 Apr; 24(4):305-14. PubMed ID: 10326868
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Hypoxia-inducible factor-1 (HIF-1) promotes its degradation by induction of HIF-alpha-prolyl-4-hydroxylases.
    Marxsen JH; Stengel P; Doege K; Heikkinen P; Jokilehto T; Wagner T; Jelkmann W; Jaakkola P; Metzen E
    Biochem J; 2004 Aug; 381(Pt 3):761-7. PubMed ID: 15104534
    [TBL] [Abstract][Full Text] [Related]  

  • 26. The pVHL-associated SCF ubiquitin ligase complex: molecular genetic analysis of elongin B and C, Rbx1 and HIF-1alpha in renal cell carcinoma.
    Clifford SC; Astuti D; Hooper L; Maxwell PH; Ratcliffe PJ; Maher ER
    Oncogene; 2001 Aug; 20(36):5067-74. PubMed ID: 11526493
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Tissue expression and plasma levels of adrenomedullin in renal cancer patients.
    Michelsen J; Thiesson H; Walter S; Ottosen PD; Skøtt O; Jensen BL
    Clin Sci (Lond); 2006 Jul; 111(1):61-70. PubMed ID: 16515534
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Expression of fibronectin and HIF-1alpha in renal cell carcinomas: relationship to von Hippel-Lindau gene inactivation.
    He Z; Liu S; Guo M; Mao J; Hughson MD
    Cancer Genet Cytogenet; 2004 Jul; 152(2):89-94. PubMed ID: 15262424
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Von Hippel-Lindau tumor suppressor protein and hypoxia-inducible factor in kidney cancer.
    Maynard MA; Ohh M
    Am J Nephrol; 2004; 24(1):1-13. PubMed ID: 14654728
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Expression of the angiopoietins and their receptor Tie2 in human renal clear cell carcinomas; regulation by the von Hippel-Lindau gene and hypoxia.
    Currie MJ; Gunningham SP; Turner K; Han C; Scott PA; Robinson BA; Chong W; Harris AL; Fox SB
    J Pathol; 2002 Dec; 198(4):502-10. PubMed ID: 12434420
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Pathology, genetics and cell biology of hemangioblastomas.
    Wizigmann-Voos S; Plate KH
    Histol Histopathol; 1996 Oct; 11(4):1049-61. PubMed ID: 8930647
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Regression of solid tumors by engineered overexpression of von Hippel-Lindau tumor suppressor protein and antisense hypoxia-inducible factor-1alpha.
    Sun X; Kanwar JR; Leung E; Vale M; Krissansen GW
    Gene Ther; 2003 Dec; 10(25):2081-9. PubMed ID: 14595381
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Von hippel-lindau disease: a genetic and clinical review.
    Haddad NM; Cavallerano JD; Silva PS
    Semin Ophthalmol; 2013; 28(5-6):377-86. PubMed ID: 24138046
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Silencing of epidermal growth factor receptor suppresses hypoxia-inducible factor-2-driven VHL-/- renal cancer.
    Smith K; Gunaratnam L; Morley M; Franovic A; Mekhail K; Lee S
    Cancer Res; 2005 Jun; 65(12):5221-30. PubMed ID: 15958567
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Hypoxia-inducible factor-1-dependent repression of E-cadherin in von Hippel-Lindau tumor suppressor-null renal cell carcinoma mediated by TCF3, ZFHX1A, and ZFHX1B.
    Krishnamachary B; Zagzag D; Nagasawa H; Rainey K; Okuyama H; Baek JH; Semenza GL
    Cancer Res; 2006 Mar; 66(5):2725-31. PubMed ID: 16510593
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Study of angiogenic signaling pathways in hemangioblastoma.
    Pierscianek D; Wolf S; Keyvani K; El Hindy N; Stein KP; Sandalcioglu IE; Sure U; Mueller O; Zhu Y
    Neuropathology; 2017 Feb; 37(1):3-11. PubMed ID: 27388534
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Identification of membrane type-1 matrix metalloproteinase as a target of hypoxia-inducible factor-2 alpha in von Hippel-Lindau renal cell carcinoma.
    Petrella BL; Lohi J; Brinckerhoff CE
    Oncogene; 2005 Feb; 24(6):1043-52. PubMed ID: 15592504
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Allelic deletions of the VHL gene detected in multiple microscopic clear cell renal lesions in von Hippel-Lindau disease patients.
    Lubensky IA; Gnarra JR; Bertheau P; Walther MM; Linehan WM; Zhuang Z
    Am J Pathol; 1996 Dec; 149(6):2089-94. PubMed ID: 8952541
    [TBL] [Abstract][Full Text] [Related]  

  • 39. The von Hippel-Lindau tumor suppressor gene and kidney cancer.
    Kaelin WG
    Clin Cancer Res; 2004 Sep; 10(18 Pt 2):6290S-5S. PubMed ID: 15448019
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Somatic VHL alteration and its impact on prognosis in patients with clear cell renal cell carcinoma.
    Kim JH; Jung CW; Cho YH; Lee J; Lee SH; Kim HY; Park J; Park JO; Kim K; Kim WS; Park YS; Im YH; Kang WK; Park K
    Oncol Rep; 2005 May; 13(5):859-64. PubMed ID: 15809750
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 49.